🔗 Share this article

While the United States proceeds with historic changes to its vaccination recommendations, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by questioning COVID-19 shots throughout the pandemic and has focused upon alleged fatalities after Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Schedule

Public health authorities planned to announce major revisions to the pediatric vaccine schedule in December, aligning the US with the Danish immunization schedule, according to reports – a major change that would place the US at odds with much of the world with insufficient data for public health gain. The announcement has been postponed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing certain childhood immunization guidelines in the US in order to be more like Denmark, a country with comprehensive healthcare and a population approximately the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccines – usually the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious experience in pharmaceutical research, oversight or management, which has been typical for former leaders of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in industry regulation.”

Previous heads of CBER would “grasp laws and regulations and the underlying principles of drug development”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who headed the center have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner stated.

“Many people just zeroes in on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There’s a biologic copycat branch, over-the-counter program and so forth, and all of those have to be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial administrative aspect to the role, which manages more than 5,000 employees. “It’s a massive leadership role, if you execute it properly,” Woodcock added.

Response and Controversial Programs

When asked about inquiries about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a press secretary stated that the “concerns rely on incorrect presumptions”.

“This background aligns with the duties of her position,” the spokesperson said, citing the period Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's recently launched fast-track approval initiative, a controversial expedited medication authorization process that reportedly concerned her predecessors. “By what process are these therapies being picked for this expedited pathway? Who is making the choices?” Dr. Howard asked. “There’s a lot of secrecy going on at the regulatory body right now.”

Overall, he remarked, “the agency seems to be moving towards more relaxed rules of most medications, except for vaccines.”

Public Track Record on Vaccines

Regarding immunizations, Høeg has a more established, if troubling, history, some experts observe. She released a study using non-validated public submissions to estimate the frequency of heart inflammation following Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who was said to have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the incoming government included revising rules for new vaccines and halting “unnecessary” immunizations, she stated post-election on a podcast. At the agency, Høeg has according to sources floated the idea of excluding adolescent males from getting Covid vaccines.

“She’s an all-around ideologue who starts off with her preconceived notions and reverse-engineers to accommodate the science in a extremely deceptive, fraudulent manner,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|